CN115916838A - Pcsk9抑制剂及其用于治疗胆固醇相关障碍的方法 - Google Patents

Pcsk9抑制剂及其用于治疗胆固醇相关障碍的方法 Download PDF

Info

Publication number
CN115916838A
CN115916838A CN202180039317.4A CN202180039317A CN115916838A CN 115916838 A CN115916838 A CN 115916838A CN 202180039317 A CN202180039317 A CN 202180039317A CN 115916838 A CN115916838 A CN 115916838A
Authority
CN
China
Prior art keywords
ldl
subject
pcsk9
hefh
pediatric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180039317.4A
Other languages
English (en)
Chinese (zh)
Inventor
A·W·哈默尔
I·M·布里奇斯
H·王
A·鲁扎
C·库尔茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CN115916838A publication Critical patent/CN115916838A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN202180039317.4A 2020-05-29 2021-05-27 Pcsk9抑制剂及其用于治疗胆固醇相关障碍的方法 Pending CN115916838A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063032451P 2020-05-29 2020-05-29
US63/032,451 2020-05-29
PCT/US2021/034489 WO2021243002A1 (en) 2020-05-29 2021-05-27 Pcsk9 inhibitors and methods of use thereof to treat cholesterol-related disorders

Publications (1)

Publication Number Publication Date
CN115916838A true CN115916838A (zh) 2023-04-04

Family

ID=78722769

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180039317.4A Pending CN115916838A (zh) 2020-05-29 2021-05-27 Pcsk9抑制剂及其用于治疗胆固醇相关障碍的方法

Country Status (11)

Country Link
US (1) US20230235085A1 (https=)
EP (1) EP4157887A4 (https=)
JP (1) JP2023527542A (https=)
CN (1) CN115916838A (https=)
AR (1) AR122180A1 (https=)
AU (1) AU2021281256A1 (https=)
CA (1) CA3179316A1 (https=)
IL (1) IL298375A (https=)
JO (1) JOP20220322A1 (https=)
TW (1) TW202210524A (https=)
WO (1) WO2021243002A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
AU2020209216A1 (en) 2019-01-18 2021-08-26 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
SG11202107614PA (en) 2019-01-18 2021-08-30 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
CN121693519A (zh) 2023-08-14 2026-03-17 信立泰(成都)生物技术有限公司 Pcsk9抑制剂用于治疗或预防胆固醇相关疾病的方法
WO2025265012A1 (en) * 2024-06-21 2025-12-26 Amgen Inc. Compositions comprising anti-pcsk9 antbodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009033743A1 (en) * 2007-09-13 2009-03-19 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
EP2706070A1 (en) * 2012-09-06 2014-03-12 Sanofi Combination treatments involving antibodies to human PCSK9
PL3169353T3 (pl) * 2014-07-16 2020-06-01 Sanofi Biotechnology SPOSOBY LECZENIA PACJENTÓW Z HETEROZYGOTYCZNĄ HIPERCHOLESTEROLEMIĄ RODZINNĄ (heFH)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RAUL D SANTOS等: "Long-Term Evolocumab in Patients With Familial Hypercholesterolemia", CLINICAL TRIAL, vol. 75, no. 06, 18 February 2020 (2020-02-18), pages 565 - 574 *

Also Published As

Publication number Publication date
WO2021243002A1 (en) 2021-12-02
IL298375A (en) 2023-01-01
TW202210524A (zh) 2022-03-16
JP2023527542A (ja) 2023-06-29
CA3179316A1 (en) 2021-12-02
AU2021281256A1 (en) 2022-12-22
EP4157887A1 (en) 2023-04-05
US20230235085A1 (en) 2023-07-27
JOP20220322A1 (ar) 2022-11-27
AR122180A1 (es) 2022-08-24
EP4157887A4 (en) 2024-07-03

Similar Documents

Publication Publication Date Title
US12331122B2 (en) Anti-ASGR-1 monoclonal inhibitory antibodies
CN115916838A (zh) Pcsk9抑制剂及其用于治疗胆固醇相关障碍的方法
EP2074149B1 (en) Compositions and methods relating to glucagon receptor antibodies
JP4898976B2 (ja) Ｐｃｓｋ９拮抗薬
US20230117883A1 (en) Muscle-targeting complexes and uses thereof in treating muscle atrophy
KR20220004985A (ko) Cd40 활성화 특성을 가진 재조합 단백질
JP7847090B2 (ja) 操作されたｂ型肝炎ウイルス中和抗体およびその使用
WO2022006557A2 (en) Anti-ctla-4 binding proteins and methods of use thereof
WO2011060076A1 (en) Anti-c-mpl antibodies
WO2020142626A1 (en) Anti-ox40 binding proteins and methods of use thereof
CN111971303B (zh) 抗cd27抗体及其用途
HK40090853A (zh) Pcsk9抑制剂及其用於治疗胆固醇相关障碍的方法
US20250289903A1 (en) Methods and compositions for treating eosinophil driven diseases and disorders
TW202228768A (zh) 用於治療疼痛之化合物及方法
CN119604534A (zh) 1型大麻素受体结合蛋白及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40090853

Country of ref document: HK